EA200601687A1 - Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 - Google Patents
Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1Info
- Publication number
- EA200601687A1 EA200601687A1 EA200601687A EA200601687A EA200601687A1 EA 200601687 A1 EA200601687 A1 EA 200601687A1 EA 200601687 A EA200601687 A EA 200601687A EA 200601687 A EA200601687 A EA 200601687A EA 200601687 A1 EA200601687 A1 EA 200601687A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- igf
- receptor
- expression
- tetragidrobenzazepinovye
- tetrahydroisoquinoline
- Prior art date
Links
- 102000038455 IGF Type 1 Receptor Human genes 0.000 title abstract 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 title abstract 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 title 2
- 230000006806 disease prevention Effects 0.000 title 1
- 230000003828 downregulation Effects 0.000 title 1
- 230000002349 favourable effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Синтезированы соединения формулы (I), в которой R, R, Rимеют значения, как приведено в описании, и U, V и W, соответственно, могут представлять собой CR', CR' и CR', (с определениями R', R' и R' снова, как в описании) или могут означать N. Показано, что они понижающим образом регулируют или ингибируют экспрессию или функцию рецептора IGF-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CH2004/000147 WO2005087743A1 (en) | 2004-03-12 | 2004-03-12 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200601687A1 true EA200601687A1 (ru) | 2007-04-27 |
Family
ID=34957074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200601687A EA200601687A1 (ru) | 2004-03-12 | 2004-03-12 | Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7875631B2 (ru) |
| EP (1) | EP1732898B1 (ru) |
| JP (1) | JP2007528877A (ru) |
| CN (1) | CN100590118C (ru) |
| AR (1) | AR049323A1 (ru) |
| AT (1) | ATE384700T1 (ru) |
| AU (1) | AU2004317166B2 (ru) |
| BR (1) | BRPI0418462A (ru) |
| CA (1) | CA2555745C (ru) |
| DE (1) | DE602004011578T2 (ru) |
| DK (1) | DK1732898T3 (ru) |
| EA (1) | EA200601687A1 (ru) |
| ES (1) | ES2299825T3 (ru) |
| IL (1) | IL177307A (ru) |
| NO (1) | NO20063794L (ru) |
| PL (1) | PL1732898T3 (ru) |
| PT (1) | PT1732898E (ru) |
| SI (1) | SI1732898T1 (ru) |
| TW (1) | TW200530213A (ru) |
| WO (1) | WO2005087743A1 (ru) |
| ZA (1) | ZA200607198B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200800785A1 (ru) * | 2005-09-09 | 2008-08-29 | Аналитикон С.А. | 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором |
| CA2621820A1 (en) * | 2005-09-09 | 2007-03-15 | Jan Gunzinger | Isoquinolines derivatives as igf-1r inhibitors |
| US8476297B2 (en) | 2007-12-04 | 2013-07-02 | Amgen Inc. | TRP-M8 receptor ligands and their use in treatments |
| US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2590944B1 (en) | 2010-07-05 | 2015-09-30 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
| US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
| EP2794563B1 (en) | 2011-12-21 | 2017-02-22 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| CN104672136B (zh) * | 2013-11-30 | 2017-01-25 | 沈阳药科大学 | 1‑取代菲基‑n‑烷基(酰基)‑6,7‑二甲氧基‑1,2,3,4‑四氢异喹啉衍生物及其制备方法和用途 |
| WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
| CN112500345B (zh) * | 2020-12-18 | 2022-06-21 | 西安石油大学 | α-氰基季碳取代四氢异喹啉化合物的合成方法 |
| WO2024067463A1 (zh) * | 2022-09-27 | 2024-04-04 | 苏州阿尔脉生物科技有限公司 | 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4349472A (en) * | 1979-04-27 | 1982-09-14 | Schering Corporation | (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| PH25651A (en) * | 1986-05-21 | 1991-08-21 | Duphar Int Res | New di, tetrahydroisoquinoline derivatives |
| WO1990002119A1 (fr) * | 1988-08-18 | 1990-03-08 | Banyu Pharmaceutical Co., Ltd. | Derives de 1,2,3,4-tetrahydro-isoquinoline |
| WO2000035455A1 (en) * | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| JP2004515494A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
| SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
| SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| GB0212303D0 (en) | 2002-05-28 | 2002-07-10 | Isis Innovation | Molecular targetting of IGF-1 receptor |
-
2004
- 2004-03-12 CA CA2555745A patent/CA2555745C/en not_active Expired - Fee Related
- 2004-03-12 PL PL04719900T patent/PL1732898T3/pl unknown
- 2004-03-12 EP EP04719900A patent/EP1732898B1/en not_active Expired - Lifetime
- 2004-03-12 DE DE602004011578T patent/DE602004011578T2/de not_active Expired - Lifetime
- 2004-03-12 AU AU2004317166A patent/AU2004317166B2/en not_active Ceased
- 2004-03-12 BR BRPI0418462-9A patent/BRPI0418462A/pt not_active IP Right Cessation
- 2004-03-12 ES ES04719900T patent/ES2299825T3/es not_active Expired - Lifetime
- 2004-03-12 AT AT04719900T patent/ATE384700T1/de active
- 2004-03-12 SI SI200430684T patent/SI1732898T1/sl unknown
- 2004-03-12 US US10/591,174 patent/US7875631B2/en not_active Expired - Fee Related
- 2004-03-12 PT PT04719900T patent/PT1732898E/pt unknown
- 2004-03-12 EA EA200601687A patent/EA200601687A1/ru unknown
- 2004-03-12 CN CN200480042030A patent/CN100590118C/zh not_active Expired - Fee Related
- 2004-03-12 JP JP2007502162A patent/JP2007528877A/ja active Pending
- 2004-03-12 DK DK04719900T patent/DK1732898T3/da active
- 2004-03-12 WO PCT/CH2004/000147 patent/WO2005087743A1/en not_active Ceased
-
2005
- 2005-02-25 TW TW094105813A patent/TW200530213A/zh unknown
- 2005-03-10 AR ARP050100920A patent/AR049323A1/es not_active Application Discontinuation
-
2006
- 2006-08-06 IL IL177307A patent/IL177307A/en not_active IP Right Cessation
- 2006-08-24 NO NO20063794A patent/NO20063794L/no not_active Application Discontinuation
- 2006-08-29 ZA ZA2006/07198A patent/ZA200607198B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN100590118C (zh) | 2010-02-17 |
| IL177307A0 (en) | 2006-12-10 |
| ZA200607198B (en) | 2008-04-30 |
| EP1732898A1 (en) | 2006-12-20 |
| DE602004011578T2 (de) | 2009-02-19 |
| CA2555745C (en) | 2011-05-31 |
| AR049323A1 (es) | 2006-07-19 |
| NO20063794L (no) | 2006-12-12 |
| CN1922147A (zh) | 2007-02-28 |
| CA2555745A1 (en) | 2005-09-22 |
| AU2004317166A1 (en) | 2005-09-22 |
| DE602004011578D1 (de) | 2008-03-13 |
| ATE384700T1 (de) | 2008-02-15 |
| WO2005087743A1 (en) | 2005-09-22 |
| ES2299825T3 (es) | 2008-06-01 |
| IL177307A (en) | 2011-09-27 |
| AU2004317166B2 (en) | 2010-11-11 |
| DK1732898T3 (da) | 2008-05-13 |
| US20070129399A1 (en) | 2007-06-07 |
| EP1732898B1 (en) | 2008-01-23 |
| PT1732898E (pt) | 2008-04-07 |
| PL1732898T3 (pl) | 2008-06-30 |
| JP2007528877A (ja) | 2007-10-18 |
| TW200530213A (en) | 2005-09-16 |
| BRPI0418462A (pt) | 2007-06-05 |
| US7875631B2 (en) | 2011-01-25 |
| SI1732898T1 (sl) | 2008-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
| BR0313176A (pt) | Composições de pirazol úteis como inibidores de gsk-3 | |
| WO2007011833A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| PL369108A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| BRPI0406801A (pt) | Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes | |
| WO2006011050A3 (en) | Pyridine derivatives | |
| WO2005065195A3 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2008054698A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| EA200601687A1 (ru) | Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 | |
| IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| WO2008036316A3 (en) | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |